Severe Combined Immunodeficiency Disease

Severe Combined Immunodeficiency Disease (SCID) is a group of rare, genetically heterogeneous disorders characterized by profound defects in both humoral and cellular immunity due to impaired development and/or function of T lymphocytes, often accompanied by abnormalities in B and sometimes natural killer (NK) cells. The pathogenesis of SCID involves mutations in genes critical for lymphocyte development, signaling, or survival, leading to a severely compromised adaptive immune system. As a result, affected individuals are highly susceptible to recurrent, severe, and often life-threatening infections by a wide range of pathogens, including bacteria, viruses, fungi, and opportunistic organisms. Without early intervention, SCID is invariably fatal within the first two years of life due to overwhelming infections, failure to thrive, and complications arising from immune dysregulation. The health impact of SCID is profound, necessitating prompt diagnosis and intervention to prevent morbidity and mortality.

X-Linked Scid (Scid-X1)

This is the most common form of SCID, accounting for approximately 40-50% of cases, and is caused by mutations in the IL2RG gene encoding the common gamma chain (γc) shared by multiple interleukin receptors. The defect results in an absence or dysfunction of T and NK cells, with non-functional B cells, leading to severe immunodeficiency. It is inherited in an X-linked recessive manner, primarily affecting males.

Adenosine Deaminase Deficiency (Ada-Scid)

ADA-SCID arises from mutations in the ADA gene, resulting in the accumulation of toxic metabolites that are particularly detrimental to lymphocyte viability. This leads to profound lymphopenia affecting T, B, and NK cells. ADA-SCID accounts for 10-15% of SCID cases and can present with additional non-immunological manifestations such as skeletal, hepatic, and neurological abnormalities.

Janus Kinase 3 Deficiency (Jak3-Scid)

Caused by mutations in the JAK3 gene, this autosomal recessive form of SCID disrupts signaling through the common gamma chain, leading to a similar immunophenotype as X-linked SCID (T− B+ NK−). It is clinically indistinguishable from X-linked SCID except for its autosomal inheritance.

Il-7 Receptor Alpha Chain Deficiency (Il7Rα-Scid)

Mutations in the IL7R gene result in defective IL-7 receptor signaling, which is essential for T-cell development. This leads to a T− B+ NK+ immunophenotype, with preserved NK cell function but absent or severely reduced T cells. It is inherited in an autosomal recessive manner.

Recombinase-Activating Gene Deficiencies (Rag1/2-Scid)

Mutations in RAG1 or RAG2 genes impair V(D)J recombination, a critical process for generating diverse antigen receptors on T and B cells. This results in the absence of both T and B lymphocytes, with preserved NK cells (T− B− NK+ phenotype). Patients may also exhibit features of Omenn syndrome, characterized by erythroderma, lymphadenopathy, and eosinophilia.

Other Rare Forms Of Scid

Additional forms of SCID arise from mutations in genes such as CD3D, CD3E, CD45, and others, each disrupting various aspects of lymphocyte development or function. These subtypes are individually rare and may exhibit unique clinical or immunological features.

Epidemiology

Severe Combined Immunodeficiency Disease is a rare disorder with an estimated incidence ranging from 1 in 40,000 to 1 in 100,000 live births worldwide, though the true prevalence may be underestimated due to underdiagnosis and early mortality. The incidence varies by population, with higher rates observed in regions with high consanguinity and founder mutations. SCID affects both males and females, but X-linked forms predominantly affect males. Newborn screening programs in several countries have improved early detection rates, leading to increased recognition of the disease and better epidemiological understanding. Mortality remains high without timely intervention, but survival rates have improved significantly with advances in early diagnosis and treatment.

Diagnosis

Diagnosis of Severe Combined Immunodeficiency Disease relies on a combination of clinical suspicion, immunological assessment, and genetic testing. Clinically, SCID should be suspected in infants presenting with recurrent, severe, or unusual infections, persistent diarrhea, failure to thrive, or adverse reactions to live vaccines. Laboratory evaluation typically reveals profound lymphopenia, particularly affecting T lymphocytes, with variable B and NK cell counts depending on the genetic subtype. Flow cytometry is used to enumerate lymphocyte subsets and assess their function, including T-cell receptor excision circles (TRECs) as a marker of recent thymic emigrants in newborn screening. Assessment of immunoglobulin levels often shows hypogammaglobulinemia. Definitive diagnosis is established through genetic testing to identify causative mutations in known SCID-associated genes. Additional diagnostic procedures may include assessment of lymphocyte proliferation in response to mitogens and evaluation for maternal T-cell engraftment. Early diagnosis, ideally through newborn screening, is critical for optimal outcomes.

Launched Drugs

Elapegademase, also known as elapegademase-lvlr, is utilized as an enzyme replacement therapy specifically for patients with adenosine deaminase-deficient Severe Combined Immunodeficiency (ADA-SCID). This recombinant enzyme serves to supplement or replace the deficient ADA activity in affected individuals, thereby reducing the accumulation of toxic purine metabolites and supporting immune system restoration. Pegademase is another recombinant adenosine deaminase enzyme replacement therapy indicated for the management of ADA-SCID. It is administered to compensate for the lack of endogenous ADA, helping to decrease purine metabolite toxicity and improve immune function in patients with this form of SCID. Both agents are integral to the therapeutic approach for ADA-SCID, offering a means to ameliorate the immunodeficiency and its associated complications.